1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" is currently closed and not accepting applications.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) National Cancer Institute (NCI). Supports research on adverse effects of cancer therapies and development of intervention strategies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profits, Small businesses, Individuals, For-profit organizations other than small businesses, Public housing authorities/Indian housing authorities, Native American tribal organizations, Faith-based organizations, Community-based organizations, Regional organizations, U.S. territories, Independent school districts, Public and State controlled institutions of higher education, Private institutions of higher education, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, Non-domestic (non-U.S.) entities, Foreign components. Confirm the full requirements in the official notice before applying.
The published deadline was March 31, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) is funded by National Institutes of Health (NIH) National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Alaska. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePAR-27-003 opens the NIGMS-style RM1 to 13 NIH institutes through September 2029: 3 to 6 PIs, up to $1.5M in direct costs a year but most awards $500K to $900K, at least 2.4 months of effort per PI, and a 20-page strategy with a mandatory Team Integration Plan. The NIGMS predecessor made 4 new awards in three years.
Read articleThe October 6, 2026 Director's Awards cohort is NIH's most expensive in four years at about $4.1 million per award. New Innovator rebounded from 29 to 42 while Early Independence fell from 13 to 3 after the program skipped its FY2026 competition. Here is what the composition shift means for FY2027 and FY2028 applicants.
Read article